26 September 2016

Kentz wins Mozambique deal

10/07/13 Harriet Russell

The company will be working in Mozambique

The company will be working in Mozambique

Engineering and construction outfit Kentz Corporation (LON:KENZ) has won a contract worth $38 million in Mozambique.

The contract is for the Nacala Corridor Project which is intended to provide the transportation of coal mined at Moatize, in Tete province to the portl located in Nacala on the coast of the Indian Ocean, via a new 912 kilometre long railway corridor. 

Kentz has been contracted to undertake the structural, mechanical and electrical erection required to construct the main stock yard equipment. Kentz will build 13 kilometres of interconnecting belt conveyors as well as assemble and install approximately 14,000 tonnes of equipment.

The contract will be executed by the construction business unit of the company which will mobilise a workforce of 700 staff and field personnel. This workforce will be primarily made up of workers local to Mozambique, the group has claimed.

The contract was awarded to Kentz by Corredor Logistico Integrado de Nacala, a joint venture company between Vale Moçambique Limitada and CFM, the Mozambique Port and Railways Authority.

The work is expected to complete in November 2014.

Shares in Kentz were trading at 400.8p this morning, valuing the company at £473 million.

Tags: Contract, Engineering, Mozambique

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

A gold medal ingredient 22/09/16

It’s hard work building a consumer brand, but Science in Sport is giving it a good go. The company has developed a range of sports nutrition products which have credibility from elite athlete users who won 34 medals at Rio.

A solid year at Brooks MacDonald 21/09/16

Fund manager Brooks MacDonald has recorded a solid year of asset growth. Funds under management grew by almost 12 per cent overall, which was a good result against a tricky market backdrop.

Styles & Wood upgraded on deal 21/09/16

Styles & Wood shares have doubled in value over the last six months as the strategy to diversify the customer base and focus on profits rather than revenue growth has gained momentum. A good set of interim results has just been followed by an earnings-enhancing acquisition.

Where's the beef? 15/09/16

Crawshaw Group shares have come crashing back to earth following a profit warning. When a highly rated growth stock hits an air pocket you run the risk of a big correction and the shares have fallen 40 per cent today.

Safestay hurt by downgrade 13/09/16

Hostel operator Safestay has released a slightly disappointing set of interim figures. Rather than becoming profitable this year there is now likely to be a small loss and the market has consequently cut back profit forecasts for the following years.

Back to basics at EKF 12/09/16

EKF Diagnostics interim results showed the benefit of refocusing on its core point-of-care (POC) diagnostics tests. Revenues were up 18 per cent, which was a welcome result after the disastrous foray into molecular diagnostics.

More News